Artal Group S.A. Protagonist Therapeutics, Inc Transaction History

Artal Group S.A.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$18.02 - $29.36 $9.01 Million - $14.7 Million	500,000 New	500,000 $13.8 Million
Q2 2022 Aug 11, 2022	SELL	$7.06 - $25.52 $5.65 Million - $20.4 Million	-800,100 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$23.34 - $36.08 $10.5 Million - $16.2 Million	-449,900 Reduced 35.99%	800,100 $18.9 Million
Q4 2021 Feb 11, 2022	SELL	$17.63 - $37.1 $4.41 Million - $9.28 Million	-250,000 Reduced 16.67%	1,250,000 $42.8 Million
Q3 2021 Nov 12, 2021	BUY	$12.95 - $49.69 $19.4 Million - $74.5 Million	1,500,000 New	1,500,000 $26.6 Million
Q2 2021 Aug 13, 2021	SELL	$25.57 - $44.88 $1.92 Million - $3.37 Million	-75,000 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$19.02 - $31.15 $1.1 Million - $1.81 Million	-58,000 Reduced 43.61%	75,000 $1.94 Million
Q3 2020 Nov 13, 2020	SELL	$15.19 - $22.4 $106,330 - $156,800	-7,000 Reduced 5.0%	133,000 $2.6 Million
Q2 2020 Aug 14, 2020	BUY	$6.19 - $18.84 $866,600 - $2.64 Million	140,000 New	140,000 $2.47 Million

247

56.4M

76.3K

114K

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $2B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.